Management of treatment failure in chronic hepatitis B.

Authors:
Address: INSERM, U1052, Cancer Research Center of Lyon, 69003 Lyon, France. fabien.zoulim@inserm.fr
Journal:

Publication:

abstract

Antiviral therapy of chronic hepatitis B remains a clinical challenge. The primary goal of therapy is to prevent liver disease progression. Because of the mechanism of viral persistence in infected hepatocytes, long-term antiviral therapy is needed in the majority of patients. Incomplete viral suppression and emergence of drug resistance is a major concern. The correct choice of a first-line potent therapy to achieve sustained long-term suppression of viral replication provides the best chance of preventing treatment failure and drug resistance. Clinical studies have demonstrated that drugs with a high barrier to resistance, such as entecavir and tenofovir, have significantly lower rates of resistance when compared with those with a low barrier to resistance such as lamivudine, adefovir, or telbivudine. Management of treatment failure requires a precise clinical and accurate virologic monitoring as well as an early treatment intervention with appropriate complementary drugs with respect to their cross-resistance profile. Long-term surveillance for treatment efficacy and possible emergence of drug resistance is necessary for those patients who have been sequentially treated with multiple antivirals. Finally, the identification of novel treatment targets remains a major research challenge to improve the efficacy of current antiviral therapy.

Related Articles
Review Management of viral hepatitis B.
J Gastroenterol Hepatol. 2002
Review Management of viral hepatitis B.
Pramoolsinsup C. J Gastroenterol Hepatol. 2002 Feb; 17 Suppl:S125-45.
Review Treatment of chronic hepatitis B: case selection and duration of therapy.
J Gastroenterol Hepatol. 2002
Review Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N. J Gastroenterol Hepatol. 2002 Apr; 17(4):409-14.
Review Chronic hepatitis B: preventing, detecting, and managing viral resistance.
Clin Gastroenterol Hepatol. 2008
Review Chronic hepatitis B: preventing, detecting, and managing viral resistance.
Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Clin Gastroenterol Hepatol. 2008 Mar; 6(3):268-74.
Review Clinical potential of emerging new agents in hepatitis B.
Drugs. 2000
Review Clinical potential of emerging new agents in hepatitis B.
Farrell GC. Drugs. 2000 Oct; 60(4):701-10.
Review Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Verh K Acad Geneeskd Belg. 2001
Review Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001; 63(5):447-73.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.